Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217992 | 0.90 | HIF1A (0.56) | SMN1; SMN2GAAHPGDNPSR1ALDH1A1 | |
| SCHEMBL14241985 | 0.83 | HIF1A (0.59) | HIF1AAAK1CA1CA2CA9 | |
| SCHEMBL5956627 | 0.80 | CA1 (0.54) | HIF1AAAK1CA1CA2CA9 | |
| SCHEMBL28571132 | 0.79 | HIF1A (0.54) | GAAALDH1A1HIF1AAAK1CA1 | |
| SCHEMBL578525 | 0.78 | HIF1A (0.53) | HIF1AAAK1CA1CA2CA9 | |
| SCHEMBL1572955 | 0.78 | HIF1A (0.56) | SMN1; SMN2ALDH1A1HIF1AAAK1CA1 | |
| SCHEMBL21217719 | 0.78 | AAK1 (0.49) | SMN1; SMN2GAAHPGDALDH1A1HIF1A | |
| SCHEMBL28493635 | 0.76 | AAK1 (0.47) | HIF1AAAK1CA1CA2CA9 | |
| SCHEMBL16468557 | 0.76 | AAK1 (0.50) | HIF1AAAK1CA1CA2CA9 | |
| SCHEMBL16468297 | 0.76 | AAK1 (0.50) | HIF1AAAK1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | SMN1; SMN2 3144/4885GAA 2236/4885HPGD 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.